Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies
F. Nissen (Basel, Switzerland), M. Humbert (Paris, France), P. Gibson (Newcastle, Australia), K. Kostikas (Ioannina, Greece), X. Jaumont (Basel, Switzerland), P. Tassinari (Basel, Switzerland), P. Pfister (Basel, Switzerland), J. Bousquet (Montigny le Bretonneux, France)
Source: International Congress 2019 – Clinical studies of asthma treatments
Session: Clinical studies of asthma treatments
Session type: Thematic Poster
Number: 2549
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Nissen (Basel, Switzerland), M. Humbert (Paris, France), P. Gibson (Newcastle, Australia), K. Kostikas (Ioannina, Greece), X. Jaumont (Basel, Switzerland), P. Tassinari (Basel, Switzerland), P. Pfister (Basel, Switzerland), J. Bousquet (Montigny le Bretonneux, France). Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies. 2549
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: